Immunology
Researchers have discovered that delivering DNA vaccines via the pulmonary route, utilizing chitosan-DNA nanoparticles, significantly enhances immunogenicity against Mycobacterium tuberculosis. The study, conducted at the Leiden/Amsterdam Center for Drug Research and Leiden University, utilized an HLA-A2 transgenic mouse model to investigate the effects of pulmonary delivery of a new
Immunology
Recent research published in the journal Vaccine has demonstrated that a CTLA-4 blockade, combined with xenogeneic DNA vaccines, significantly enhances T-cell responses and tumor immunity in animal and cellular model systems. This study, led by Polly D. Gregor at the Memorial Sloan-Kettering Cancer Center, investigated the potential of CTLA-4 blockade
Pharmaceutical industry
ID Biomedical Corp. and Shire Pharmaceuticals Group, plc, have signed an asset purchase agreement related to the sale of Shire's vaccine business to ID Biomedical. The transaction, which is conditional on approval by the Canadian government and regulatory approvals, is expected to close by June 30, 2004. Under
Pharmaceutical industry
Richard B. Brewer, a seasoned executive with nearly 30 years of biopharmaceutical industry experience, has been appointed to the board of directors at Corgentech, Inc. Brewer's background and expertise include building companies and commercializing products, particularly in the cardiovascular and pharmaceutical sectors. He brings a wealth of knowledge
